Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees

Acta Virologica

Volumn 40, Issue 3, 1996, Pages 157-170

  Friedrich, F ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

attenuation; genome modifications; mutations; neurovirulence; poliovirus; recombination; Sabin vaccine strains; vacci nation associated cases

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

DNA MODIFICATION; HUMAN; NEUROPATHY; POLIOMYELITIS VIRUS; REVIEW; SAFETY; VACCINATION; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS RECOMBINATION; VIRUS VIRULENCE;

ANIMALS; FACIAL PARALYSIS; GENOME, VIRAL; HUMANS; MYELITIS, TRANSVERSE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLYRADICULONEUROPATHY; VACCINATION; VACCINES, ATTENUATED; VIRULENCE;

MIRIDAE; POLIOVIRUS;

EID: 0029794339     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Abe S, Ota Y, Koike S, Kurata T, Horie H, Nomura T, Hashizume S, Nomoto A (1995a): Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice. Virology 206, 1075-1083
2. Abe S, OtaY, Doi Y, Nomoto A, Nomura T, Chumakov KM, Hashizume S (1995b): Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature-sensitive viruses derived from the Sabin type 3 virus. Virology 210, 160-166.
3. Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL (1993): Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J. Infect. Dis. 168, 1105-1109.
4. Agol VI, Drozdov SG, Ivannikova TA, Kolesnikova MS, Korolev MB, Tolskaya EA (1989): Restricted growth of attenuated poliovirus strains in cultured cells of a human neuroblastoma. J. Virol. 63, 4034-4038.
5. Agol VI (1991): The 5′-untranslated region of picornaviral genomes. Adv. Virus Res. 40, 103-180.
6. Agol VI (1993): Genetic stability and instability of the cis-acting control element of the 5′ untranslated region of the poliovirus RNA. Dev. Biol. Stand. 78, 11-16.
7. Almond JW, Westrop GD, Cann AJ, Stanway G, Evans DMA, Minor PD, Schild, GC (1985): Attenuation and reversion to neurovirulence of the Sabin poliovirus type 3 vaccine. In Lener RA, Chanock RM, Brown F (Ed.): Vaccines 85. New York, Cold Spring Harbor Laboratory, pp. 271-277.
8. Almond JW (1987):The attenuation of poliovirus neurovirulence. Ann. Rev. Microbiol. 41, 153-180.
9. Arya SC (1994): Vaccine-associated poliomyelitis. Lancet 343, 610-611.
10. Barak Y, Schwartz JF (1988): Acute transverse myelitis associated with Echo type 5 infection. Amer. J. Dis. Child. 142, 128.
11. Basilico FC, Bernat JL (1978): Vaccine-associated poliomyelitis in a contact. JAMA 239, 2275.
12. Bolton CF (1995): The changing concepts of Guillain-Barré syndrome. New Engl. J. Med. 333, 1415-1417.
13. Borzakian S, Pelletier I, Calvez V, Colbere-Garapin F (1993): Precise missense and silent point mutations are fixed in the genomes of poliovirus mutants from persistently infected cells. J. Virol 67, 2914-2917.
14. Bouchard MJ, Lam DH, Racaniello VR (1995): Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J. Virol. 69, 4972-4978.
15. Caldas C, Bernicker E, Nogare AD, Luby JP (1994): Transverse myelitis associated with Epstein-Barr virus infection. Amer. J. Med. Sci. 307, 45-48.
16. Cammack N, Phillips A, Dunn G, Patel V, Minor PD (1988): Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 167, 507-514.
17. Cann AJ, Stanway G, Hughes PJ, Minor PD, Evans DMA, Schild GC, Almond JW (1984): Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 12, 7787-7792.
18. Christodoulou C, Colbere-Garapin F, Macadam A, Taffs LF, Marsden S, Minor P, Horaud F (1990): Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J. Virol. 64, 4922-4929.
19. Chumakov KM, Powers LB, Noonan KE, Roninson IB, Levenbook IS (1991): Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc. Natl. Acad. Sci. USA 88, 199-203.
20. Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran Y, Levenbook IS (1992): RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J. Virology 66, 966-970.
21. Chumakov K, Norwood L, Parker M, Dragunsky E, Taffs R, Ran Y, Ridge J, Levenbook I (1993): Assesment of the viral RNA sequence heterogeneity for control of OPV neurovirulence. Dev. Biol. Stand. 78, 79-89.
22. Chumakov KM, Dragunsky EM, Norwood LP, Douthitt MP, Ran Y, Taffs RE, Ridge J, Levenbook IS (1994): Consistent selection of mutations in the 5′-untranslated region of oral poliovirus vaccine upon passaging in vitro. J. Med. Virol. 42, 79-85.
23. Colbere-Garapin F, Christodoulou C, Crainic R, Pelletier I (1989): Persistent poliovirus infection of human neuroblastoma cells. Proc. Natl. Acad. Sci. USA 86, 7590-7594.
24. Contreras G, Dimock K, Furesz J, Gardell C, Hazlett D, Karpinski K, McCorkle G, Wu L (1992): Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals 20, 15-26.
25. D'Costa DF, Cooper A, Pye IF (1990): Transverse myelitis following cholera, typhoid and polio vaccination. J. Roy. Soc. Med. 83, 653.
26. Dodson D (1990): Transverse myelitis and spastic paraparesis in a patient with HIV infection. New Engl. J. Med. 322, 1322.
27. Driesel G, Diedrich S, Künkel U, Schreier E (1995): Vaccine-associated cases of poliomyelitis over a 30 year period in East Germany. Europ. J. Epidemiol. 11, 1-8.
28. Dunn G, Begg NT, Cammack N, Minor PD (1990): Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J. Med. Virol. 32, 92-95.
29. Ehrenfeld E (1992): International workshop: 'Poliovirus attenuation: molecular mechanisms and practical aspects'. Biologicals 20, 167-169.
30. Evans DMA, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel JrJV (1995): Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314, 548-550.
31. Equestre M, Genovese D, Cavaliere F, Fiore L, Santoro R, Perez Bercoff R (1991): Identification of a consistent pattern of mutations in neurovirulent variants derived from the Sabin vaccine strain of poliovirus type 2. J. Virol. 65, 2707-2710.
32. Fenyves A (1993): The potencial use of viral genomic markers in estimating the neurovirulence of oral poliomyelitis vac-cine (OPV): Regulatory aspects. Dev. Biol. Stand. 78, 157-159.
33. Filippis AMB, Schatzmayr HG, Fcrreira FC, Chagas SAR, Costa MC, Santos AP, Da Silva EE (1994): Intratypic differentiation of polioviruses isolated from suspected cases of poliomyelitis in Brazil during the period of 1990 to 1993. Mem. Inst. Oswaldo Cruz 89, 513-518.
34. Fiore L, Pierangeli A, Lombardi F, Santoro R, Crainic R, Venuti A, Perez Bercoff R (1987): Antigenic and biochemical characterization of poliovirus type 2 isolated from two cases of paralytic disease. Intervirology 27, 196-204.
35. Friedrich F, Filippis AMB, Ferreira FC, Schatzmayr HG, Da Silva EE (1995a): Genomic characterization of type 1 Sabin-related polioviruses isolated in Brazil. Acta Virol. 39, 23-29.
36. Friedrich F, Filippis AMB, Fcrreira FC, Schatzmayr HG, Da Silva EE (1995b): Genomic characterization of type 2 polioviruses isolated from vaccine-associated cases in Brazil. Brazil. J. Med. Biol. Res. 28, 733-742.
37. Friedrich F, Filippis AMB, Ferreira FC, Schatzmayr HG, Da Silva EE (1995c): Genomic characterization of type 3 polioviruses isolated from vaccine-associated poliomyelitis cases in Brazil. Brazil. J. Med. Biol. Res. 28, 195-200.
38. Friedrich F, Filippis AMB, Schatzmayr HG (1995d): Sabin-related poliovirus vaccine strains isolated from transverse myelitis cases in Brazil. Rev. Inst. Med. Trop S. Paulo 37, 543-545.
39. Friedrich F, Filippis AMB, Ferreira FC, Oliveira MJC, Schatzmayr HG, Da Silva EE (1996a): Poliovirus type 1 isolated from a vaccine-associated case of paralytic poliomyelitis in Brazil. Brazil. J. Med. Biol. Res. 29, 15-18.
40. Friedrich F, Filippis AMB, Schatzmayr HG (1996b): Temporal association between the isolation of Sabin-related poliovirus vaccine strains and the Guillain-Barré syndrome. Rev. Inst. Med. Trop. S. Paulo 38, 55-58.
41. Friedrich F, Da Silva EE, Schatzmayr HG (1996c): Type 2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil. Acta Virol. 40, 27-33.
42. Furione M, Guillot S, Otelca D, Balanant J, Candrea A, Crainic R (1993): Poliovirus with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196, 199-208.
43. Georgescu MM, Delpeyroux F, Tardy-Panit M, Balanant J, Combiescu M, Combiescu AA, Guillot S, Crainic R (1994): High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 68, 8089-8101.
44. Georgescu MM, Delpeyroux F, Crainic R (1995a): Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus. J. Gen. Virol 76, 2343-2348.
45. Georgescu MM, Tardy-Panit M, Guillot S, Crainic R, Delpeyroux F (1995b): Mapping of mutations contributing to the temperature sensitivity of the Sabin I vaccine strain of poliovirus. J. Virol. 69, 5278-5286.
46. Ghendon Y (1993): WHO Recommendation on potencial use of new poliomyelitis vaccines. Dev. Biol. Stand. 78, 133-139.
47. 9 virus infection. Pediat. Infect. Dis. J. 13, 77.
48. Groom SN, Clewley J, Litton PA, Brown DW (1994): Vaccine-associated poliomyelitis. Lancet 343, 609-610.
49. Guillot S, Otelea D, Delpeyroux F, Crainic R (1994): Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine 12, 503-507.
50. Hellen CUT, Pestova TV, Litterst M, Wimmer E (1994): The cellular polypeptide p57 (pyrimidine tract-binding protein) binds to multiple sites in the poliovirus 5′ untranslated region. J. Virol. 68, 941-950.
51. Heller HM, Carnevale NT, Steigbigel RT (1990): Varicella zoster virus transverse myelitis without cutaneous rash. Amer. J. Med. 88, 550-551.
52. Hill AE, Hicks EM, Coyle PV (1994): Human herpes virus 6 and central nervous system complications. Develop. Med. Child. Neurol. 36, 651-652
53. Hogle JM, Chow M, Filman DJ (1985): Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229, 1358-1365.
54. Holt S, Hudgins D, Krishnan KR, Critchley EMR (1976): Diffuse myelitis associated wiht rubella vaccination. Brit. Med. J. 30, 1037-1038.
55. Horaud F (1993): Albert B. Sabin and the development of oral poliovaccine. Biologicals 21, 311-316.
56. Horie H, Koike S, Kurata T, Sato-Yoshida Y, Ise I, Ota Y, Abe S, Hioki K, Kato H, Taya C, Nomura T, Hashizume S, Yonekawa H, Nomoto A (1994):Transgenic mice earring the human poliovirus receptor: new animal model for study of poliovirus neurovirulence. J. Virol. 68, 681-688.
57. Hughes PJ, Evans DMA, Minor PD, Schild GC, Almond JW, Stanway G (1986): The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland. J. Gen. Virol. 67, 2093-2102.
58. Ion-Nedelcu N, Dobrescu A, Strebel PM, Sutter RW (1994): Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet 343, 51-52.
59. Jarousse N, Grant RA, Hogle JM, Zhang L, Senkowski A, Roos RP, Michiels T, Brahic M, McAllister A (1994): A single amino acid change determines persistence of a chimeric Theiler's virus. J. Virol. 68, 3364-3368
60. Johnston ICD, Usherwood EJ, Nash AA, Brown TDK (1995): Theiler's murine encephalomyelitis virus 3D RNA polymerase: its expression in the CNS and the specific immune response generated in persistently infected mice. J. Gen. Virol. 76, 2765-2778.
61. Kawamura N, Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A (1989): Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63, 1302-1309.
62. Kew OM, Nottay BK, Hatch MH, Nakano JH, Obijeski JF (1981): Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J. Gen. Virol. 56, 337-347.
63. Kinnunen E, Färkkilä M, Hovi T, Juntunen J, Weckström P (1989): Incidence of Guillain-Barré syndrome during a nationwide oral poliovirus vaccine campaign. Neurology 39, 1034-1036.
64. Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, Emini EA, Hanecak R, Lee JJ, Van Der Werf S, Anderson CW, Wimmer E (1981): Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature 291, 547-553.
65. Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H, Nomoto A (1991): Transgenic mice susceptible to poliovirus. Proc. Natl. Acad. Sci. USA 88, 951-955.
66. Koike S, Horie H, Sato Y, Ise I, Taya C, Nomura T, Yoshioka I, Yonekawa H, Nomoto A (1993): Poliovirus-sensitive transgenic mice as a new animal model. Dev. Biol. Stand. 78, 101-107.
67. Hughes PJ, Evans, DMA., Minor, PD, Schild, GC, Almond, GW, and Sanway, G. (1986): The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland. J. Gen. Virol. 67, 2093-2102.
68. La Monica N, Meriam C, Racaniello VR (1986): Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing. J. Virol. 57, 515-525.
69. La Monica N, Almond JW, Racaniello VR (1987): A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans. J. Virol. 61, 2917-2920.
70. La Monica N, Racaniello VR (1989): Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y. J. Virol, 63, 2357-2360.
71. Lederman HM, Winkelstein JA (1985): X-Linked Agammaglobulinemia: an analysis of 96 patients. Medicine 64, 145-156.
72. Leneman F (1966): The Guillain-Barré syndrome. Arch. Intern. Med. 118, 139-144.
73. Lipskaya GY, Muzychenko AR, Kutitova OK, Maslova SV, Equestre M, Drozdov SG, Perez Bercoff R, Agol VI (1991): Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J. Med. Virol. 35, 290-296.
74. Macadam AJ, Arnold C, Hewlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J, Cammack N, Minor PD (1989): Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172, 408-414.
75. Macadam AJ, Pollard SR, Ferguson G, Dunn G, Skuce R, Almond JW, Minor PD (1991a): The 5′noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 181, 451-458.
76. Macadam AJ, Ferguson G, Arnold C, Minor PD (1991b): An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. J. Virology 65, 5225-5231.
77. Macadam AJ, Ferguson G, Burlison J, Stone D, Skuce R, Almond JW, Minor PD (1992): Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology 189, 415-422.
78. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD (1993): Genetic Basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192, 18-26.
79. Macadam AJ, Ferguson G, Fleming T, Stone DM, Almond JW, Minor PD (1994a): Role for poliovirus protcase 2A in cap independent translation. EMBO J. 13, 924-927.
80. Macadam AJ, Stone DM, Almond JW, Minor PD (1994b): The 5′ noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol. 2, 449-454.
81. Martin A, Benichou D, Courdec T, Hogle JM, Wychowski C, Van der Werf S, Girard M (1991): Use oftype 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. Virology 180, 648-658.
82. McGoldrick A, Macadam AJ, Dunn G, Rowe A, Burlison J, Minor PD, Meredith J, Evans DJ, Almond JW (1995): Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J. Virol 69, 7601-7605.
83. Meerovitch K, Pelletier J, Sonenberg N (1989): A cellular protein that binds to the 5′-noncoding region of poliovirus RNA: implications for internal translation initiation. Genes Dev. 3, 1026-1034.
84. Melnick JL (1993): The discovery of the Enteroviruses and the classification of poliovirus among them. Biologicals 21, 305-309.
85. Melnick JL, Horaud F (1993): Albert B. Sabin. Biologicals 21, 299-303.
86. Mento SJ, Weeks-Levy C, Tatem JM, Gorgacz EJ, Waterfield WF (1993): Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine. Dev. Biol. Stand. 78, 93-100.
87. Michiels T, Jarousse N, Brahic M (1995): Analysis of the leader and capsid coding regions of persistent and neurovirulent strains of Theiler's virus. Virology 214, 550-558.
88. Miles C, Hoffman W, Lai CW, Freeman JW (1993): Cytomegalovirus- associated transverse myelitis. Neurology 43, 2143-2145.
89. Minor PD (1982): Characterization of strains of type 3 poliovirus by oligonucleotide mapping. J. Gen. Virol. 59, 307-317.
90. Minor PD, John A, Ferguson M, Icenogle JP (1986): Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretation by a primary vaccince. J. Gen. Virol. 67, 693-706.
91. Minor PD, Dunn G (1988): The effect of sequences in the 5′ noncoding region on the replication of polioviruses in the human gut. J. Gen. Virol. 69, 1091-1096.
92. Minor PD, Dunn G, Evans DMA, Magrath DI, John A, Hewlett J, Phillips A, Wcstrop G, Wareham K, Almond JW, Hogle JM (1989): The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J. Gen. Virol. 70, 1117-1123.
93. Minor PD (1992): The molecular biology of poliovaccines. J. Gen. Virol. 73, 3065-3077.
94. Minor PD (1993): Attenuation and reversion of the Sabin vaccine strains of poliovirus. Dev. Biol. Stand. 78, 17-26.
95. Minor PD, Macadam A J, Stone DM, Almond JW (1993): Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 21, 357-363.
96. Moss EG, O'Neil RE, Racaniello VR (1989): Mapping of attenuating sequences of an avirulent poliovirus type 2 strain. J. Virol. 63, 1884-1890.
97. Muzychenko AR, Lipskaya GY, Maslova SV, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM, Agol VI (1991): Coupled mutations in the 5′- untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. Virus Res. 21, 111-122.
98. Nkowane BM, Wassilak SGF, Orenstcin WA, Bart KJ, Schonberger LB, Hinman AR, Kew OM (1987): Vaccine-associated paralytic poliomyelitis in the United States: 1973 through 1984. JAMA 257, 1335-1340.
99. Nomoto A, Omata T, Toyoda H, Kuge S, Horie H, Kataoka Y, Genba Y, Nakano Y, Imura N (1982): Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc. Natl. Acad. Sci. USA 79, 5793-5797.
100. Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD (1991): Effect of prior immunity on the shedding of virulent revertant virus in faeces after oral immunization with live attenuated poliovirus vaccines. J. Infect. Dis. 164, 191-194.
101. Omata T, Kohara M, Kuge S, Komatsu T, Abe S, Semler BL, Kameda A, Itoh H, Arita M, Wimmer E, Nomoto A (1986): Genetic analysis of the attenuation phenotype of poliovirus type 1. J. Virol. 58, 348-358.
102. Otelea D, Guillot S, Furione M, Combiescu AA, Balanant J, Candrea A, Crainic R (1993): Genomic modifications in naturally occuring neurovirulent revertants of Sabin 1 polioviruses. Dev. Biol. Stand. 78, 33-38.
103. Pelletier I, Couderc T, Borzakian S, Wyckoff E, Crainic R, Ehrenfeld E, Colbere-Garapin F (1991): Characterization of persistent poliovirus mutants selected in human neuroblastoma cells. Virology 180, 729-737.
104. Pilipenko EV, Blinov VM, Romanova LI, Sinyakov AN, Maslova SV, Agol VI (1989): Conserved structural domains in the 5′-untranslated region of picornaviral genomes: an analysis of the segment controlling translation and neurovirulence. Virology 168, 201-209.
105. Pollard SR, Dunn G, Cammack N, Minor PD, Almond JW (1989): Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J. Virol. 63, 4949-4951.
106. Racaniello VR, Baltimore D (1981a): Cloned poliovirus complementary DNA is infectious in mammalian cells. Science, 214, 916-919.
107. Racaniello VR, Baltimore D (1981b): Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc. Natl. Acad. Sci. USA 78, 4887-4891.
108. Racaniello VR (1988): Poliovirus neurovirulence. Adv. Virus Res. 34, 217-246.
109. Racaniello VR, Ren R, Bouchard M (1993): Poliovirus attenuation and pathogenesis in a transgenic mouse model for poliomyelitis. Dev. Biol. Stand. 78, 109-116.
110. Racaniello VR (1993): Infectious cDNA, cell receptors and transgenic mice in the study of Sabin's poliovirus vaccines. Biologicals 21, 365-369.
111. Ren R, Costantini F, Gorgacz EJ, Lee JJ Racaniello VR (1990): Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63, 353-362.
112. Ren R, Moss EG, Racaniello VR (1991): Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J. Virol. 65, 1377-1382.
113. Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS (1994): Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology 202, 370-378.
114. Rczapkin GV, Norwood LP, Taffs RE, Dragunsky EM, Levenbook IS, Chumakov KM (1995): Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control. Virology 211, 377-384.
115. Ropper AH (1992): The Guillain-Barré syndrome. New Engl. J. Med 326, 1130-1136.
116. Skinner MA, Racaniello VR, Dunn G, Cooper J, Minor PD, Almond JW (1989): New model for the secondary structure of the 5′ non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J. Mol. Biol. 207, 379-392.
117. 1b: comparison with poliovirus type 1. Nucleic Acids Res. 11, 5629-5643.
118. 1b. Proc. Natl. Acad. Sci. USA 81, 1539-1543.
119. Stratton KR, Howe CJ, Johnston RB (1994): Adverse events associated with childhood vaccines other than pertussis and rubella. JAMA 271, 1602-1605.
120. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR (1992): Epidemiology of poliomyelitis in the United States one decade after the last report case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14, 568-579.
121. Strebel PM, Aubert-Combiescu A, Ion-Nedelcu N, Biberi-Moroeanu S, Combiescu M, Sutter RW, Kew OM, Pallansch MA, Patriarca PA, Cochi SL (1994): Paralytic poliomyelitis in Romania, 1984-1992: Evidence for a high risk of vaccine-associated disease and reintroduction of wild- virus infection. Am. J. Epidemiol. 140, 1111-1124.
122. Strebel PM, Ion-Nedelcu N, Baughman AL, Sutler RW, Cochi SL (1995): Intramuscular injections within 30 days of immunization with oral poliovirus vaccine - a risk factor for vaccine-associated paralytic poliomyelitis. N. Engl. J. Med. 332, 500-506.
123. Svitkin YV, Maslova SV, Agol VI (1985): The genomes of attenuated and virulent poliovirus strains differ in their in vitro translation efficiencies. Virology 147, 243-252.
124. Svitkin YV, Pestova TV, Maslova SV, Agol VI (1988): Point mutations modify the response of poliovirus RNA to a translation initiation factor: a comparison of neurovirulent and attenuated strains. Virology 166, 394-404.
125. Svitkin YV, Cammack N, Minor PD, Almond JW (1990): Translation deficiency of the Sabin type 3 poliovirus genonic: association with an attenuating mutation C472->U. Virology 175, 103-109.
126. Svitkin YV, Alpatova GA, Lipskaya GA, Maslova SV, Agol VI, Kew O, Meerovitch K, Sonenberg N (1993): Towards development of an in vitro translation test for poliovirus neurovirulence. Dev. Biol. Stand. 78, 27-32.
127. Taffs RE, Chumakov KM, Rezapkin GV, Lu Z, Douthitt M, Dragunsky EM, Levenbook IS (1995): Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology 209, 366-373.
128. Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F (1993): A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuattion in mice. J. Virol. 67, 4630-4638.
129. Tatem JM, Weeks-Levy C, Mento SJ, DiMichele SJ, Georgiu A, Waterfield WF, Sheip B, Costalas C, Davics T, Ritchey MB, Cano FR (1991): Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees. J. Med. Virol. 35, 101-109.
130. Tatem JM, Weeks-Levy C, Georgiu A, DiMichele SJ, Gorgacz EJ, Racaniello VR, Cano FR, Mento SJ (1992): A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J. Virol. 66, 3194-3197.
131. Toyoda H, Kohara M, Kataoka Y, Suganuma T, Omata T, Imura N, Nomoto A (1984): Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J. Mol. Biol. 174, 561-585.
132. Uhari M, Rantala H, Niemelä M (1989): Cluster of childhood Guillnin- Barré cases after an oral poliovaccine campaign. Lancet 2, 440-441.
133. Vahidy F, Kazmi K, Rab SM (1989): Transverse myelitis and hepatites in varicella. J. Trop. Med. Hyg. 92, 295-296.
134. Weeks-Levy C, Tatem JM, DiMichele SJ, Waterfield W, Georgiu AF, Mento SJ (1991): Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology 185, 934-937. - Erratum (1992): Virology 187, 845.
135. Westrop GD, Wareham KA, Evans DMA, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW (1989): Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63, 1338-1344.
136. Wimmer E, Nomoto A (1993): Molecular biology and cell-free synthesis of poliovirus. Biologicals 21, 349-356.
137. Whittle E, Roberton NRC (1977): Transverse myelitis after diphtheria, tetanus, and polio immunization. Brit. Med. J. 1, 1450.
138. WHO (1982): The relation between acute persisting spinal paralysis and poliomyelitis vaccine - results of a ten-year enquiry. Bull. WHO 60, 231-242.
139. WHO (1990): Potencial use of new poliomyelitis vaccines: Memorandum from a WHO meeting. Bull. WHO 68, 545-548.
140. Wyatt HV (1994): Vaccine-associated poliomyelitis. Lancet 343, 610.
141. 233-244. J. Immunol. 153, 4508-4519.
142. Zuckerman MA, Brink NS, Kyi M, Tedder RS (1994): Exposure of immunocompromised individuals to health-care workers immunized with oral poliovaccine. Lancet 343, 985-986.